nodes	percent_of_prediction	percent_of_DWPC	metapath
Asenapine—CYP1A2—Carmustine—melanoma	0.0905	0.229	CbGbCtD
Asenapine—CYP1A2—Vemurafenib—melanoma	0.0715	0.181	CbGbCtD
Asenapine—CYP3A4—Temozolomide—melanoma	0.0684	0.173	CbGbCtD
Asenapine—CYP2D6—Vemurafenib—melanoma	0.0589	0.149	CbGbCtD
Asenapine—CYP1A2—Dacarbazine—melanoma	0.0548	0.139	CbGbCtD
Asenapine—CYP3A4—Vemurafenib—melanoma	0.0375	0.095	CbGbCtD
Asenapine—HTR1D—meninx—melanoma	0.022	0.302	CbGeAlD
Asenapine—CYP3A4—Docetaxel—melanoma	0.0129	0.0326	CbGbCtD
Asenapine—Localized exfoliation—Bleomycin—melanoma	0.00768	0.0405	CcSEcCtD
Asenapine—Electrocardiogram QT prolonged—Vemurafenib—melanoma	0.00531	0.028	CcSEcCtD
Asenapine—Traumatic liver injury—Temozolomide—melanoma	0.00468	0.0247	CcSEcCtD
Asenapine—HTR5A—head—melanoma	0.00386	0.053	CbGeAlD
Asenapine—Sinus tachycardia—Docetaxel—melanoma	0.00288	0.0152	CcSEcCtD
Asenapine—HTR2A—hindlimb—melanoma	0.0026	0.0357	CbGeAlD
Asenapine—HTR1B—blood vessel—melanoma	0.00258	0.0354	CbGeAlD
Asenapine—HTR1D—blood vessel—melanoma	0.0025	0.0343	CbGeAlD
Asenapine—Pain in extremity—Vemurafenib—melanoma	0.00248	0.0131	CcSEcCtD
Asenapine—Extrapyramidal disorder—Temozolomide—melanoma	0.00232	0.0122	CcSEcCtD
Asenapine—HTR2A—appendage—melanoma	0.00223	0.0306	CbGeAlD
Asenapine—Ulcer—Bleomycin—melanoma	0.00219	0.0115	CcSEcCtD
Asenapine—HTR7—endothelium—melanoma	0.00216	0.0296	CbGeAlD
Asenapine—Liver injury—Temozolomide—melanoma	0.00207	0.0109	CcSEcCtD
Asenapine—Ulcer—Dactinomycin—melanoma	0.00204	0.0108	CcSEcCtD
Asenapine—Wheezing—Bleomycin—melanoma	0.00201	0.0106	CcSEcCtD
Asenapine—HTR7—blood vessel—melanoma	0.00199	0.0273	CbGeAlD
Asenapine—Amenorrhoea—Temozolomide—melanoma	0.00198	0.0105	CcSEcCtD
Asenapine—Skin exfoliation—Bleomycin—melanoma	0.00197	0.0104	CcSEcCtD
Asenapine—HRH2—skin of body—melanoma	0.00181	0.0249	CbGeAlD
Asenapine—Pulmonary embolism—Carmustine—melanoma	0.0018	0.00952	CcSEcCtD
Asenapine—Pulmonary embolism—Temozolomide—melanoma	0.00174	0.0092	CcSEcCtD
Asenapine—Mouth ulceration—Dactinomycin—melanoma	0.00174	0.00919	CcSEcCtD
Asenapine—Skin exfoliation—Carmustine—melanoma	0.00172	0.00909	CcSEcCtD
Asenapine—Oedema peripheral—Vemurafenib—melanoma	0.00169	0.0089	CcSEcCtD
Asenapine—Connective tissue disorder—Vemurafenib—melanoma	0.00168	0.00888	CcSEcCtD
Asenapine—Skin exfoliation—Temozolomide—melanoma	0.00166	0.00878	CcSEcCtD
Asenapine—HTR1E—head—melanoma	0.00165	0.0226	CbGeAlD
Asenapine—Gynaecomastia—Carmustine—melanoma	0.00161	0.00852	CcSEcCtD
Asenapine—Eye disorder—Vemurafenib—melanoma	0.0016	0.00845	CcSEcCtD
Asenapine—Cardiac disorder—Vemurafenib—melanoma	0.00159	0.00839	CcSEcCtD
Asenapine—Angiopathy—Vemurafenib—melanoma	0.00155	0.0082	CcSEcCtD
Asenapine—Mediastinal disorder—Vemurafenib—melanoma	0.00154	0.00814	CcSEcCtD
Asenapine—Diabetes mellitus—Carmustine—melanoma	0.00151	0.00794	CcSEcCtD
Asenapine—Malnutrition—Vemurafenib—melanoma	0.00149	0.00787	CcSEcCtD
Asenapine—Swelling—Carmustine—melanoma	0.00148	0.00783	CcSEcCtD
Asenapine—Dysgeusia—Vemurafenib—melanoma	0.00146	0.0077	CcSEcCtD
Asenapine—HTR7—neck—melanoma	0.00142	0.0195	CbGeAlD
Asenapine—HTR2A—endothelium—melanoma	0.00135	0.0185	CbGeAlD
Asenapine—DRD3—head—melanoma	0.00134	0.0184	CbGeAlD
Asenapine—HTR1D—eye—melanoma	0.00133	0.0182	CbGeAlD
Asenapine—Amenorrhoea—Docetaxel—melanoma	0.00132	0.00696	CcSEcCtD
Asenapine—Hyponatraemia—Carmustine—melanoma	0.00132	0.00694	CcSEcCtD
Asenapine—HTR6—head—melanoma	0.00129	0.0177	CbGeAlD
Asenapine—Arthralgia—Vemurafenib—melanoma	0.00127	0.0067	CcSEcCtD
Asenapine—HTR2A—blood vessel—melanoma	0.00124	0.017	CbGeAlD
Asenapine—Anaphylactic shock—Vemurafenib—melanoma	0.00122	0.00642	CcSEcCtD
Asenapine—Dysphagia—Dactinomycin—melanoma	0.00121	0.00638	CcSEcCtD
Asenapine—Inflammation—Docetaxel—melanoma	0.0012	0.00631	CcSEcCtD
Asenapine—Nervous system disorder—Vemurafenib—melanoma	0.00119	0.0063	CcSEcCtD
Asenapine—HRH2—head—melanoma	0.00118	0.0162	CbGeAlD
Asenapine—Pulmonary embolism—Docetaxel—melanoma	0.00116	0.00612	CcSEcCtD
Asenapine—Breast disorder—Temozolomide—melanoma	0.00114	0.00603	CcSEcCtD
Asenapine—Hypotension—Vemurafenib—melanoma	0.00114	0.006	CcSEcCtD
Asenapine—Dysphagia—Carmustine—melanoma	0.00113	0.00597	CcSEcCtD
Asenapine—Neutropenia—Dactinomycin—melanoma	0.00113	0.00597	CcSEcCtD
Asenapine—Stomatitis—Bleomycin—melanoma	0.00113	0.00595	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Temozolomide—melanoma	0.00112	0.00589	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Vemurafenib—melanoma	0.00111	0.00585	CcSEcCtD
Asenapine—Skin exfoliation—Docetaxel—melanoma	0.00111	0.00584	CcSEcCtD
Asenapine—Dysphagia—Temozolomide—melanoma	0.00109	0.00577	CcSEcCtD
Asenapine—HTR2B—skin of body—melanoma	0.00108	0.0148	CbGeAlD
Asenapine—Neutropenia—Carmustine—melanoma	0.00106	0.00558	CcSEcCtD
Asenapine—Stomatitis—Dactinomycin—melanoma	0.00105	0.00554	CcSEcCtD
Asenapine—Gastrointestinal disorder—Vemurafenib—melanoma	0.00105	0.00554	CcSEcCtD
Asenapine—Fatigue—Vemurafenib—melanoma	0.00105	0.00554	CcSEcCtD
Asenapine—Constipation—Vemurafenib—melanoma	0.00104	0.00549	CcSEcCtD
Asenapine—Neutropenia—Temozolomide—melanoma	0.00102	0.0054	CcSEcCtD
Asenapine—Hyperglycaemia—Carmustine—melanoma	0.00102	0.00539	CcSEcCtD
Asenapine—Depression—Carmustine—melanoma	0.00101	0.00531	CcSEcCtD
Asenapine—Agranulocytosis—Dactinomycin—melanoma	0.00101	0.00531	CcSEcCtD
Asenapine—DRD2—eye—melanoma	0.001	0.0137	CbGeAlD
Asenapine—Weight increased—Temozolomide—melanoma	0.000996	0.00525	CcSEcCtD
Asenapine—DRD2—retina—melanoma	0.000992	0.0136	CbGeAlD
Asenapine—Hyperglycaemia—Temozolomide—melanoma	0.000987	0.00521	CcSEcCtD
Asenapine—Stomatitis—Carmustine—melanoma	0.000984	0.00519	CcSEcCtD
Asenapine—Depression—Temozolomide—melanoma	0.000973	0.00513	CcSEcCtD
Asenapine—DRD1—head—melanoma	0.000962	0.0132	CbGeAlD
Asenapine—Swelling—Docetaxel—melanoma	0.000954	0.00503	CcSEcCtD
Asenapine—Stomatitis—Temozolomide—melanoma	0.000951	0.00501	CcSEcCtD
Asenapine—Hepatobiliary disease—Temozolomide—melanoma	0.000922	0.00487	CcSEcCtD
Asenapine—Hypersensitivity—Vemurafenib—melanoma	0.000897	0.00473	CcSEcCtD
Asenapine—Oedema peripheral—Carmustine—melanoma	0.000893	0.00471	CcSEcCtD
Asenapine—Connective tissue disorder—Carmustine—melanoma	0.00089	0.0047	CcSEcCtD
Asenapine—HTR2A—neck—melanoma	0.000888	0.0122	CbGeAlD
Asenapine—Dermatitis bullous—Docetaxel—melanoma	0.000881	0.00465	CcSEcCtD
Asenapine—Asthenia—Vemurafenib—melanoma	0.000873	0.00461	CcSEcCtD
Asenapine—Oedema peripheral—Temozolomide—melanoma	0.000863	0.00455	CcSEcCtD
Asenapine—Connective tissue disorder—Temozolomide—melanoma	0.00086	0.00454	CcSEcCtD
Asenapine—Eye disorder—Carmustine—melanoma	0.000847	0.00447	CcSEcCtD
Asenapine—Hyponatraemia—Docetaxel—melanoma	0.000845	0.00446	CcSEcCtD
Asenapine—Pain in extremity—Docetaxel—melanoma	0.000842	0.00444	CcSEcCtD
Asenapine—Anaemia—Bleomycin—melanoma	0.000835	0.00441	CcSEcCtD
Asenapine—HRH2—lymph node—melanoma	0.000828	0.0114	CbGeAlD
Asenapine—Eye disorder—Temozolomide—melanoma	0.000818	0.00432	CcSEcCtD
Asenapine—Malaise—Bleomycin—melanoma	0.000815	0.0043	CcSEcCtD
Asenapine—Cardiac disorder—Temozolomide—melanoma	0.000813	0.00429	CcSEcCtD
Asenapine—Leukopenia—Bleomycin—melanoma	0.000809	0.00427	CcSEcCtD
Asenapine—Dizziness—Vemurafenib—melanoma	0.000805	0.00425	CcSEcCtD
Asenapine—Angiopathy—Temozolomide—melanoma	0.000794	0.00419	CcSEcCtD
Asenapine—Mental disorder—Carmustine—melanoma	0.000794	0.00419	CcSEcCtD
Asenapine—Immune system disorder—Temozolomide—melanoma	0.000791	0.00417	CcSEcCtD
Asenapine—HRH1—eye—melanoma	0.00079	0.0108	CbGeAlD
Asenapine—Mediastinal disorder—Temozolomide—melanoma	0.000789	0.00416	CcSEcCtD
Asenapine—Malnutrition—Carmustine—melanoma	0.000789	0.00416	CcSEcCtD
Asenapine—HTR1B—head—melanoma	0.000779	0.0107	CbGeAlD
Asenapine—Anaemia—Dactinomycin—melanoma	0.000779	0.00411	CcSEcCtD
Asenapine—Vomiting—Vemurafenib—melanoma	0.000774	0.00408	CcSEcCtD
Asenapine—ADRA2C—mammalian vulva—melanoma	0.000772	0.0106	CbGeAlD
Asenapine—Orthostatic hypotension—Docetaxel—melanoma	0.000769	0.00405	CcSEcCtD
Asenapine—Rash—Vemurafenib—melanoma	0.000768	0.00405	CcSEcCtD
Asenapine—Mental disorder—Temozolomide—melanoma	0.000767	0.00405	CcSEcCtD
Asenapine—Dermatitis—Vemurafenib—melanoma	0.000767	0.00404	CcSEcCtD
Asenapine—Headache—Vemurafenib—melanoma	0.000763	0.00402	CcSEcCtD
Asenapine—Malnutrition—Temozolomide—melanoma	0.000762	0.00402	CcSEcCtD
Asenapine—Breast disorder—Docetaxel—melanoma	0.000761	0.00401	CcSEcCtD
Asenapine—Malaise—Dactinomycin—melanoma	0.00076	0.00401	CcSEcCtD
Asenapine—HTR1D—head—melanoma	0.000754	0.0104	CbGeAlD
Asenapine—Leukopenia—Dactinomycin—melanoma	0.000754	0.00398	CcSEcCtD
Asenapine—HTR2C—head—melanoma	0.000747	0.0103	CbGeAlD
Asenapine—Dysgeusia—Temozolomide—melanoma	0.000746	0.00394	CcSEcCtD
Asenapine—Alanine aminotransferase increased—Docetaxel—melanoma	0.000742	0.00392	CcSEcCtD
Asenapine—Tremor—Carmustine—melanoma	0.000739	0.0039	CcSEcCtD
Asenapine—Anaphylactic shock—Bleomycin—melanoma	0.000737	0.00389	CcSEcCtD
Asenapine—ADRB1—head—melanoma	0.000733	0.0101	CbGeAlD
Asenapine—Anaemia—Carmustine—melanoma	0.000729	0.00385	CcSEcCtD
Asenapine—Dysphagia—Docetaxel—melanoma	0.000728	0.00384	CcSEcCtD
Asenapine—Agitation—Carmustine—melanoma	0.000725	0.00382	CcSEcCtD
Asenapine—Nausea—Vemurafenib—melanoma	0.000723	0.00381	CcSEcCtD
Asenapine—Thrombocytopenia—Bleomycin—melanoma	0.000722	0.00381	CcSEcCtD
Asenapine—Tremor—Temozolomide—melanoma	0.000714	0.00377	CcSEcCtD
Asenapine—SLC6A4—head—melanoma	0.000708	0.00972	CbGeAlD
Asenapine—Leukopenia—Carmustine—melanoma	0.000706	0.00372	CcSEcCtD
Asenapine—Anaemia—Temozolomide—melanoma	0.000705	0.00372	CcSEcCtD
Asenapine—HTR2B—head—melanoma	0.000702	0.00963	CbGeAlD
Asenapine—Agitation—Temozolomide—melanoma	0.0007	0.00369	CcSEcCtD
Asenapine—Angioedema—Temozolomide—melanoma	0.000696	0.00367	CcSEcCtD
Asenapine—Hypotension—Bleomycin—melanoma	0.000689	0.00363	CcSEcCtD
Asenapine—Malaise—Temozolomide—melanoma	0.000687	0.00363	CcSEcCtD
Asenapine—Convulsion—Carmustine—melanoma	0.000683	0.0036	CcSEcCtD
Asenapine—Leukopenia—Temozolomide—melanoma	0.000682	0.0036	CcSEcCtD
Asenapine—Hypertension—Carmustine—melanoma	0.000681	0.00359	CcSEcCtD
Asenapine—Neutropenia—Docetaxel—melanoma	0.00068	0.00359	CcSEcCtD
Asenapine—Thrombocytopenia—Dactinomycin—melanoma	0.000673	0.00355	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Bleomycin—melanoma	0.000672	0.00354	CcSEcCtD
Asenapine—Anxiety—Carmustine—melanoma	0.000669	0.00353	CcSEcCtD
Asenapine—Weight increased—Docetaxel—melanoma	0.000662	0.00349	CcSEcCtD
Asenapine—Convulsion—Temozolomide—melanoma	0.00066	0.00348	CcSEcCtD
Asenapine—HTR2A—eye—melanoma	0.00066	0.00906	CbGeAlD
Asenapine—Hypertension—Temozolomide—melanoma	0.000658	0.00347	CcSEcCtD
Asenapine—Dyspnoea—Bleomycin—melanoma	0.000657	0.00347	CcSEcCtD
Asenapine—HTR2A—retina—melanoma	0.000654	0.00898	CbGeAlD
Asenapine—Arthralgia—Temozolomide—melanoma	0.000649	0.00342	CcSEcCtD
Asenapine—Anxiety—Temozolomide—melanoma	0.000647	0.00341	CcSEcCtD
Asenapine—Dry mouth—Temozolomide—melanoma	0.000635	0.00335	CcSEcCtD
Asenapine—Stomatitis—Docetaxel—melanoma	0.000632	0.00333	CcSEcCtD
Asenapine—Thrombocytopenia—Carmustine—melanoma	0.00063	0.00332	CcSEcCtD
Asenapine—HTR1A—head—melanoma	0.000629	0.00863	CbGeAlD
Asenapine—Tachycardia—Carmustine—melanoma	0.000628	0.00331	CcSEcCtD
Asenapine—HRH1—mammalian vulva—melanoma	0.000627	0.00861	CbGeAlD
Asenapine—Musculoskeletal discomfort—Dactinomycin—melanoma	0.000627	0.00331	CcSEcCtD
Asenapine—Anaphylactic shock—Temozolomide—melanoma	0.000622	0.00328	CcSEcCtD
Asenapine—ADRA2A—mammalian vulva—melanoma	0.000616	0.00846	CbGeAlD
Asenapine—Hepatobiliary disease—Docetaxel—melanoma	0.000613	0.00324	CcSEcCtD
Asenapine—Nervous system disorder—Temozolomide—melanoma	0.00061	0.00322	CcSEcCtD
Asenapine—Thrombocytopenia—Temozolomide—melanoma	0.000609	0.00321	CcSEcCtD
Asenapine—Agranulocytosis—Docetaxel—melanoma	0.000605	0.00319	CcSEcCtD
Asenapine—Hypotension—Carmustine—melanoma	0.000602	0.00317	CcSEcCtD
Asenapine—HTR7—head—melanoma	0.000601	0.00825	CbGeAlD
Asenapine—Fatigue—Dactinomycin—melanoma	0.000593	0.00313	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Carmustine—melanoma	0.000587	0.00309	CcSEcCtD
Asenapine—Insomnia—Carmustine—melanoma	0.000582	0.00307	CcSEcCtD
Asenapine—ADRA1A—head—melanoma	0.00058	0.00796	CbGeAlD
Asenapine—Dyspnoea—Carmustine—melanoma	0.000574	0.00303	CcSEcCtD
Asenapine—Oedema peripheral—Docetaxel—melanoma	0.000574	0.00303	CcSEcCtD
Asenapine—Somnolence—Carmustine—melanoma	0.000572	0.00302	CcSEcCtD
Asenapine—Connective tissue disorder—Docetaxel—melanoma	0.000572	0.00302	CcSEcCtD
Asenapine—DRD2—head—melanoma	0.000568	0.0078	CbGeAlD
Asenapine—Musculoskeletal discomfort—Temozolomide—melanoma	0.000567	0.00299	CcSEcCtD
Asenapine—Insomnia—Temozolomide—melanoma	0.000563	0.00297	CcSEcCtD
Asenapine—Gastrointestinal disorder—Carmustine—melanoma	0.000556	0.00293	CcSEcCtD
Asenapine—Dyspnoea—Temozolomide—melanoma	0.000555	0.00293	CcSEcCtD
Asenapine—Somnolence—Temozolomide—melanoma	0.000553	0.00292	CcSEcCtD
Asenapine—ADRA2C—head—melanoma	0.000552	0.00758	CbGeAlD
Asenapine—Constipation—Carmustine—melanoma	0.00055	0.0029	CcSEcCtD
Asenapine—Dyspepsia—Temozolomide—melanoma	0.000548	0.00289	CcSEcCtD
Asenapine—Eye disorder—Docetaxel—melanoma	0.000544	0.00287	CcSEcCtD
Asenapine—Hypersensitivity—Bleomycin—melanoma	0.000543	0.00287	CcSEcCtD
Asenapine—Cardiac disorder—Docetaxel—melanoma	0.00054	0.00285	CcSEcCtD
Asenapine—Gastrointestinal disorder—Temozolomide—melanoma	0.000537	0.00283	CcSEcCtD
Asenapine—Fatigue—Temozolomide—melanoma	0.000536	0.00283	CcSEcCtD
Asenapine—Constipation—Temozolomide—melanoma	0.000532	0.00281	CcSEcCtD
Asenapine—Asthenia—Bleomycin—melanoma	0.000529	0.00279	CcSEcCtD
Asenapine—Angiopathy—Docetaxel—melanoma	0.000528	0.00279	CcSEcCtD
Asenapine—Immune system disorder—Docetaxel—melanoma	0.000526	0.00277	CcSEcCtD
Asenapine—Mediastinal disorder—Docetaxel—melanoma	0.000525	0.00277	CcSEcCtD
Asenapine—Mental disorder—Docetaxel—melanoma	0.00051	0.00269	CcSEcCtD
Asenapine—Malnutrition—Docetaxel—melanoma	0.000507	0.00267	CcSEcCtD
Asenapine—Hypersensitivity—Dactinomycin—melanoma	0.000507	0.00267	CcSEcCtD
Asenapine—Dysgeusia—Docetaxel—melanoma	0.000496	0.00262	CcSEcCtD
Asenapine—Asthenia—Dactinomycin—melanoma	0.000493	0.0026	CcSEcCtD
Asenapine—HTR2B—lymph node—melanoma	0.000491	0.00674	CbGeAlD
Asenapine—Muscle spasms—Docetaxel—melanoma	0.000487	0.00257	CcSEcCtD
Asenapine—Hypersensitivity—Carmustine—melanoma	0.000474	0.0025	CcSEcCtD
Asenapine—Vomiting—Bleomycin—melanoma	0.000469	0.00247	CcSEcCtD
Asenapine—Anaemia—Docetaxel—melanoma	0.000469	0.00247	CcSEcCtD
Asenapine—Rash—Bleomycin—melanoma	0.000465	0.00245	CcSEcCtD
Asenapine—Dermatitis—Bleomycin—melanoma	0.000465	0.00245	CcSEcCtD
Asenapine—Asthenia—Carmustine—melanoma	0.000462	0.00244	CcSEcCtD
Asenapine—Hypersensitivity—Temozolomide—melanoma	0.000458	0.00242	CcSEcCtD
Asenapine—Syncope—Docetaxel—melanoma	0.000455	0.0024	CcSEcCtD
Asenapine—Leukopenia—Docetaxel—melanoma	0.000454	0.00239	CcSEcCtD
Asenapine—HRH1—head—melanoma	0.000449	0.00616	CbGeAlD
Asenapine—Asthenia—Temozolomide—melanoma	0.000446	0.00235	CcSEcCtD
Asenapine—Loss of consciousness—Docetaxel—melanoma	0.000446	0.00235	CcSEcCtD
Asenapine—ADRA2A—head—melanoma	0.000441	0.00605	CbGeAlD
Asenapine—Convulsion—Docetaxel—melanoma	0.000439	0.00232	CcSEcCtD
Asenapine—Nausea—Bleomycin—melanoma	0.000438	0.00231	CcSEcCtD
Asenapine—Hypertension—Docetaxel—melanoma	0.000438	0.00231	CcSEcCtD
Asenapine—Vomiting—Dactinomycin—melanoma	0.000437	0.00231	CcSEcCtD
Asenapine—Rash—Dactinomycin—melanoma	0.000434	0.00229	CcSEcCtD
Asenapine—Arthralgia—Docetaxel—melanoma	0.000432	0.00228	CcSEcCtD
Asenapine—Dizziness—Carmustine—melanoma	0.000426	0.00225	CcSEcCtD
Asenapine—Dry mouth—Docetaxel—melanoma	0.000422	0.00223	CcSEcCtD
Asenapine—Anaphylactic shock—Docetaxel—melanoma	0.000414	0.00218	CcSEcCtD
Asenapine—Dizziness—Temozolomide—melanoma	0.000411	0.00217	CcSEcCtD
Asenapine—Vomiting—Carmustine—melanoma	0.000409	0.00216	CcSEcCtD
Asenapine—Nausea—Dactinomycin—melanoma	0.000409	0.00215	CcSEcCtD
Asenapine—Shock—Docetaxel—melanoma	0.000407	0.00215	CcSEcCtD
Asenapine—Rash—Carmustine—melanoma	0.000406	0.00214	CcSEcCtD
Asenapine—Nervous system disorder—Docetaxel—melanoma	0.000406	0.00214	CcSEcCtD
Asenapine—Dermatitis—Carmustine—melanoma	0.000406	0.00214	CcSEcCtD
Asenapine—Thrombocytopenia—Docetaxel—melanoma	0.000405	0.00214	CcSEcCtD
Asenapine—Tachycardia—Docetaxel—melanoma	0.000404	0.00213	CcSEcCtD
Asenapine—Headache—Carmustine—melanoma	0.000403	0.00213	CcSEcCtD
Asenapine—Vomiting—Temozolomide—melanoma	0.000396	0.00209	CcSEcCtD
Asenapine—Rash—Temozolomide—melanoma	0.000392	0.00207	CcSEcCtD
Asenapine—Dermatitis—Temozolomide—melanoma	0.000392	0.00207	CcSEcCtD
Asenapine—Headache—Temozolomide—melanoma	0.00039	0.00206	CcSEcCtD
Asenapine—ADRA2C—lymph node—melanoma	0.000387	0.00531	CbGeAlD
Asenapine—Hypotension—Docetaxel—melanoma	0.000387	0.00204	CcSEcCtD
Asenapine—Nausea—Carmustine—melanoma	0.000382	0.00202	CcSEcCtD
Asenapine—Musculoskeletal discomfort—Docetaxel—melanoma	0.000377	0.00199	CcSEcCtD
Asenapine—HTR2A—head—melanoma	0.000375	0.00514	CbGeAlD
Asenapine—Insomnia—Docetaxel—melanoma	0.000374	0.00197	CcSEcCtD
Asenapine—Nausea—Temozolomide—melanoma	0.00037	0.00195	CcSEcCtD
Asenapine—Dyspnoea—Docetaxel—melanoma	0.000369	0.00195	CcSEcCtD
Asenapine—Somnolence—Docetaxel—melanoma	0.000368	0.00194	CcSEcCtD
Asenapine—Dyspepsia—Docetaxel—melanoma	0.000364	0.00192	CcSEcCtD
Asenapine—Gastrointestinal disorder—Docetaxel—melanoma	0.000357	0.00188	CcSEcCtD
Asenapine—Fatigue—Docetaxel—melanoma	0.000357	0.00188	CcSEcCtD
Asenapine—Constipation—Docetaxel—melanoma	0.000354	0.00187	CcSEcCtD
Asenapine—CYP2D6—head—melanoma	0.000341	0.00469	CbGeAlD
Asenapine—HRH1—lymph node—melanoma	0.000314	0.00431	CbGeAlD
Asenapine—ADRA2A—lymph node—melanoma	0.000309	0.00424	CbGeAlD
Asenapine—Hypersensitivity—Docetaxel—melanoma	0.000305	0.00161	CcSEcCtD
Asenapine—Asthenia—Docetaxel—melanoma	0.000297	0.00157	CcSEcCtD
Asenapine—Dizziness—Docetaxel—melanoma	0.000274	0.00144	CcSEcCtD
Asenapine—Vomiting—Docetaxel—melanoma	0.000263	0.00139	CcSEcCtD
Asenapine—Rash—Docetaxel—melanoma	0.000261	0.00138	CcSEcCtD
Asenapine—Dermatitis—Docetaxel—melanoma	0.000261	0.00137	CcSEcCtD
Asenapine—Headache—Docetaxel—melanoma	0.000259	0.00137	CcSEcCtD
Asenapine—Nausea—Docetaxel—melanoma	0.000246	0.0013	CcSEcCtD
Asenapine—DRD4—Signaling Pathways—PIK3CA—melanoma	5.27e-06	1.53e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CCND1—melanoma	5.26e-06	1.53e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PIK3CB—melanoma	5.26e-06	1.53e-05	CbGpPWpGaD
Asenapine—ADRA1A—GPCR downstream signaling—AKT1—melanoma	5.25e-06	1.53e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—VEGFA—melanoma	5.22e-06	1.52e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CTNNB1—melanoma	5.21e-06	1.52e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CASP3—melanoma	5.2e-06	1.52e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—IL2—melanoma	5.2e-06	1.51e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—VEGFA—melanoma	5.19e-06	1.51e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—TP53—melanoma	5.18e-06	1.51e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CCND1—melanoma	5.17e-06	1.51e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—IL6—melanoma	5.17e-06	1.51e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—STAT3—melanoma	5.17e-06	1.51e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—MAPK3—melanoma	5.16e-06	1.5e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CCND1—melanoma	5.16e-06	1.5e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—KRAS—melanoma	5.16e-06	1.5e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PPARG—melanoma	5.16e-06	1.5e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—NRAS—melanoma	5.16e-06	1.5e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—STAT3—melanoma	5.14e-06	1.5e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—NRAS—melanoma	5.13e-06	1.49e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CTNNB1—melanoma	5.12e-06	1.49e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MAPK3—melanoma	5.12e-06	1.49e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CTNNB1—melanoma	5.11e-06	1.49e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MMP9—melanoma	5.1e-06	1.49e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—HRAS—melanoma	5.1e-06	1.48e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—TP53—melanoma	5.1e-06	1.48e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—KRAS—melanoma	5.09e-06	1.48e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—HRAS—melanoma	5.09e-06	1.48e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—CDKN1A—melanoma	5.09e-06	1.48e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PTEN—melanoma	5.07e-06	1.48e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CCND1—melanoma	5.07e-06	1.48e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—HRAS—melanoma	5.06e-06	1.47e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CXCL8—melanoma	5.05e-06	1.47e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—VEGFA—melanoma	5.05e-06	1.47e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MAPK3—melanoma	5.05e-06	1.47e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—NFKB1—melanoma	5.05e-06	1.47e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—PIK3CA—melanoma	5.03e-06	1.47e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MMP9—melanoma	5.02e-06	1.46e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—MYC—melanoma	5.02e-06	1.46e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—HRAS—melanoma	5.02e-06	1.46e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CTNNB1—melanoma	5.02e-06	1.46e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MMP9—melanoma	5.01e-06	1.46e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—CDKN1A—melanoma	5e-06	1.46e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—STAT3—melanoma	5e-06	1.46e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—CDKN1A—melanoma	4.99e-06	1.46e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PTEN—melanoma	4.99e-06	1.45e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—NRAS—melanoma	4.99e-06	1.45e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PTEN—melanoma	4.98e-06	1.45e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MYC—melanoma	4.98e-06	1.45e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—NFKB1—melanoma	4.97e-06	1.45e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—NFKB1—melanoma	4.96e-06	1.44e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—HRAS—melanoma	4.95e-06	1.44e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling by GPCR—AKT1—melanoma	4.95e-06	1.44e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MAPK3—melanoma	4.94e-06	1.44e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CDKN1B—melanoma	4.93e-06	1.44e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MMP9—melanoma	4.92e-06	1.43e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MAPK3—melanoma	4.91e-06	1.43e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—MAPK1—melanoma	4.91e-06	1.43e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MYC—melanoma	4.91e-06	1.43e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—EGFR—melanoma	4.91e-06	1.43e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—CDKN1A—melanoma	4.9e-06	1.43e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PTEN—melanoma	4.89e-06	1.42e-05	CbGpPWpGaD
Asenapine—ADRA2A—GPCR downstream signaling—AKT1—melanoma	4.88e-06	1.42e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—IL6—melanoma	4.88e-06	1.42e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—HRAS—melanoma	4.87e-06	1.42e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—IL6—melanoma	4.87e-06	1.42e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling by GPCR—AKT1—melanoma	4.87e-06	1.42e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—MAPK1—melanoma	4.87e-06	1.42e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—EGFR—melanoma	4.87e-06	1.42e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—NFKB1—melanoma	4.87e-06	1.42e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—TP53—melanoma	4.86e-06	1.42e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling by GPCR—AKT1—melanoma	4.86e-06	1.42e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ABCB1—melanoma	4.85e-06	1.41e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—IL6—melanoma	4.84e-06	1.41e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CASP3—melanoma	4.84e-06	1.41e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—IL2—melanoma	4.83e-06	1.41e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—MAPK1—melanoma	4.81e-06	1.4e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—EGFR—melanoma	4.8e-06	1.4e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—IL6—melanoma	4.8e-06	1.4e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MYC—melanoma	4.8e-06	1.4e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MAPK3—melanoma	4.78e-06	1.39e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MYC—melanoma	4.78e-06	1.39e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling by GPCR—AKT1—melanoma	4.77e-06	1.39e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	4.75e-06	1.38e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—PIK3CA—melanoma	4.74e-06	1.38e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—IL6—melanoma	4.74e-06	1.38e-05	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—PIK3CA—melanoma	4.72e-06	1.37e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CCND1—melanoma	4.71e-06	1.37e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CD—melanoma	4.7e-06	1.37e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—MAPK1—melanoma	4.7e-06	1.37e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—EGFR—melanoma	4.7e-06	1.37e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—PIK3CA—melanoma	4.68e-06	1.36e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—MAPK1—melanoma	4.67e-06	1.36e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—EGFR—melanoma	4.67e-06	1.36e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—IL6—melanoma	4.66e-06	1.36e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CTNNB1—melanoma	4.66e-06	1.36e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—HRAS—melanoma	4.65e-06	1.36e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MYC—melanoma	4.65e-06	1.35e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—KRAS—melanoma	4.64e-06	1.35e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—ALB—melanoma	4.64e-06	1.35e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—KRAS—melanoma	4.6e-06	1.34e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—TP53—melanoma	4.59e-06	1.34e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—VEGFA—melanoma	4.58e-06	1.34e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MMP9—melanoma	4.57e-06	1.33e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—CDKN1A—melanoma	4.55e-06	1.33e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—MAPK1—melanoma	4.55e-06	1.32e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—EGFR—melanoma	4.55e-06	1.32e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PTEN—melanoma	4.54e-06	1.32e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—KRAS—melanoma	4.54e-06	1.32e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—STAT3—melanoma	4.54e-06	1.32e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CG—melanoma	4.53e-06	1.32e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—NRAS—melanoma	4.53e-06	1.32e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—TP53—melanoma	4.53e-06	1.32e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—NFKB1—melanoma	4.52e-06	1.32e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—VEGFA—melanoma	4.51e-06	1.31e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—VEGFA—melanoma	4.5e-06	1.31e-05	CbGpPWpGaD
Asenapine—HTR6—Signaling Pathways—AKT1—melanoma	4.5e-06	1.31e-05	CbGpPWpGaD
Asenapine—HTR7—Signaling Pathways—AKT1—melanoma	4.49e-06	1.31e-05	CbGpPWpGaD
Asenapine—HTR1D—Signaling Pathways—AKT1—melanoma	4.47e-06	1.3e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—STAT3—melanoma	4.47e-06	1.3e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PRKCA—melanoma	4.46e-06	1.3e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—STAT3—melanoma	4.46e-06	1.3e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—NRAS—melanoma	4.45e-06	1.3e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—IL6—melanoma	4.45e-06	1.3e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—NRAS—melanoma	4.44e-06	1.3e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—KRAS—melanoma	4.44e-06	1.29e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling by GPCR—AKT1—melanoma	4.43e-06	1.29e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ERCC2—melanoma	4.43e-06	1.29e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—VEGFA—melanoma	4.42e-06	1.29e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—KRAS—melanoma	4.42e-06	1.29e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—HRAS—melanoma	4.39e-06	1.28e-05	CbGpPWpGaD
Asenapine—HTR1B—Signaling Pathways—AKT1—melanoma	4.37e-06	1.27e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—STAT3—melanoma	4.37e-06	1.27e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PPARG—melanoma	4.37e-06	1.27e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—NRAS—melanoma	4.36e-06	1.27e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MAPK3—melanoma	4.34e-06	1.26e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—HRAS—melanoma	4.33e-06	1.26e-05	CbGpPWpGaD
Asenapine—DRD4—Signaling Pathways—AKT1—melanoma	4.3e-06	1.25e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—KRAS—melanoma	4.29e-06	1.25e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MAPK3—melanoma	4.27e-06	1.24e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—PIK3CA—melanoma	4.26e-06	1.24e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MAPK3—melanoma	4.26e-06	1.24e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—PIK3CA—melanoma	4.22e-06	1.23e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MYC—melanoma	4.22e-06	1.23e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—IL6—melanoma	4.2e-06	1.22e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MAPK3—melanoma	4.18e-06	1.22e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—PIK3CA—melanoma	4.17e-06	1.22e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MYC—melanoma	4.15e-06	1.21e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—IL6—melanoma	4.14e-06	1.21e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MYC—melanoma	4.14e-06	1.21e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—MAPK1—melanoma	4.13e-06	1.2e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—EGFR—melanoma	4.12e-06	1.2e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—TP53—melanoma	4.12e-06	1.2e-05	CbGpPWpGaD
Asenapine—HTR2B—Signaling Pathways—AKT1—melanoma	4.11e-06	1.2e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—VEGFA—melanoma	4.1e-06	1.2e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CB—melanoma	4.1e-06	1.19e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—TP53—melanoma	4.09e-06	1.19e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—PIK3CA—melanoma	4.08e-06	1.19e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MYC—melanoma	4.06e-06	1.18e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—STAT3—melanoma	4.06e-06	1.18e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—MAPK1—melanoma	4.06e-06	1.18e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTGS2—melanoma	4.06e-06	1.18e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—EGFR—melanoma	4.06e-06	1.18e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—PIK3CA—melanoma	4.06e-06	1.18e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—NRAS—melanoma	4.05e-06	1.18e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—MAPK1—melanoma	4.05e-06	1.18e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—EGFR—melanoma	4.05e-06	1.18e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—TP53—melanoma	4.03e-06	1.18e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CD—melanoma	3.98e-06	1.16e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—MAPK1—melanoma	3.97e-06	1.16e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—EGFR—melanoma	3.97e-06	1.16e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—PIK3CA—melanoma	3.95e-06	1.15e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—TP53—melanoma	3.94e-06	1.15e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—HRAS—melanoma	3.94e-06	1.15e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—ALB—melanoma	3.93e-06	1.15e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—TP53—melanoma	3.92e-06	1.14e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—HRAS—melanoma	3.91e-06	1.14e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—KRAS—melanoma	3.9e-06	1.14e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MAPK3—melanoma	3.88e-06	1.13e-05	CbGpPWpGaD
Asenapine—DRD1—Signaling Pathways—AKT1—melanoma	3.87e-06	1.13e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—HRAS—melanoma	3.86e-06	1.12e-05	CbGpPWpGaD
Asenapine—ADRA2C—Metabolism—AKT1—melanoma	3.85e-06	1.12e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—KRAS—melanoma	3.83e-06	1.12e-05	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—PIK3CA—melanoma	3.83e-06	1.12e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—KRAS—melanoma	3.83e-06	1.11e-05	CbGpPWpGaD
Asenapine—DRD3—Signaling Pathways—AKT1—melanoma	3.82e-06	1.11e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—TP53—melanoma	3.82e-06	1.11e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MYC—melanoma	3.77e-06	1.1e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—IL6—melanoma	3.77e-06	1.1e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—HRAS—melanoma	3.77e-06	1.1e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—KRAS—melanoma	3.75e-06	1.09e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—HRAS—melanoma	3.75e-06	1.09e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—IL6—melanoma	3.74e-06	1.09e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—MAPK1—melanoma	3.69e-06	1.08e-05	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—IL6—melanoma	3.69e-06	1.08e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—EGFR—melanoma	3.69e-06	1.08e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—HRAS—melanoma	3.65e-06	1.06e-05	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—IL6—melanoma	3.61e-06	1.05e-05	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—IL6—melanoma	3.59e-06	1.05e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—PIK3CA—melanoma	3.58e-06	1.04e-05	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PTEN—melanoma	3.54e-06	1.03e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—PIK3CA—melanoma	3.52e-06	1.03e-05	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—PIK3CA—melanoma	3.51e-06	1.02e-05	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CG—melanoma	3.5e-06	1.02e-05	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—IL6—melanoma	3.49e-06	1.02e-05	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—KRAS—melanoma	3.49e-06	1.02e-05	CbGpPWpGaD
Asenapine—ADRB1—Signaling Pathways—AKT1—melanoma	3.48e-06	1.01e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CB—melanoma	3.47e-06	1.01e-05	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—TP53—melanoma	3.46e-06	1.01e-05	CbGpPWpGaD
Asenapine—ADRA2B—Signaling Pathways—AKT1—melanoma	3.45e-06	1.01e-05	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—PIK3CA—melanoma	3.45e-06	1e-05	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTGS2—melanoma	3.44e-06	1e-05	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—TP53—melanoma	3.41e-06	9.93e-06	CbGpPWpGaD
Asenapine—ADRB2—Signaling Pathways—AKT1—melanoma	3.41e-06	9.93e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—TP53—melanoma	3.4e-06	9.91e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PPARG—melanoma	3.37e-06	9.83e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—TP53—melanoma	3.34e-06	9.72e-06	CbGpPWpGaD
Asenapine—HTR1A—Signaling Pathways—AKT1—melanoma	3.33e-06	9.71e-06	CbGpPWpGaD
Asenapine—HTR2C—Signaling Pathways—AKT1—melanoma	3.31e-06	9.66e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—HRAS—melanoma	3.31e-06	9.65e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—HRAS—melanoma	3.26e-06	9.5e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—HRAS—melanoma	3.25e-06	9.48e-06	CbGpPWpGaD
Asenapine—ADRA2C—Signaling Pathways—AKT1—melanoma	3.22e-06	9.39e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—PIK3CA—melanoma	3.2e-06	9.34e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—HRAS—melanoma	3.19e-06	9.3e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—IL6—melanoma	3.17e-06	9.24e-06	CbGpPWpGaD
Asenapine—ADRA2A—Metabolism—AKT1—melanoma	3.13e-06	9.12e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—IL6—melanoma	3.12e-06	9.09e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—IL6—melanoma	3.11e-06	9.07e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—TP53—melanoma	3.1e-06	9.03e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CD—melanoma	3.07e-06	8.95e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—IL6—melanoma	3.05e-06	8.9e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—ALB—melanoma	3.03e-06	8.84e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PTEN—melanoma	3e-06	8.74e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—HRAS—melanoma	2.96e-06	8.64e-06	CbGpPWpGaD
Asenapine—DRD2—Signaling Pathways—AKT1—melanoma	2.92e-06	8.52e-06	CbGpPWpGaD
Asenapine—HTR2A—Signaling Pathways—AKT1—melanoma	2.88e-06	8.38e-06	CbGpPWpGaD
Asenapine—HRH1—Signaling Pathways—AKT1—melanoma	2.87e-06	8.37e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—IL6—melanoma	2.84e-06	8.27e-06	CbGpPWpGaD
Asenapine—ADRA1A—Signaling Pathways—AKT1—melanoma	2.82e-06	8.21e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CB—melanoma	2.68e-06	7.8e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTGS2—melanoma	2.65e-06	7.73e-06	CbGpPWpGaD
Asenapine—ADRA2A—Signaling Pathways—AKT1—melanoma	2.62e-06	7.63e-06	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—PIK3CA—melanoma	2.5e-06	7.28e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PTEN—melanoma	2.31e-06	6.74e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—PIK3CA—melanoma	2.12e-06	6.16e-06	CbGpPWpGaD
Asenapine—CYP2D6—Metabolism—AKT1—melanoma	2.04e-06	5.94e-06	CbGpPWpGaD
Asenapine—CYP1A2—Metabolism—AKT1—melanoma	1.73e-06	5.04e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—PIK3CA—melanoma	1.63e-06	4.76e-06	CbGpPWpGaD
Asenapine—CYP3A4—Metabolism—AKT1—melanoma	1.33e-06	3.89e-06	CbGpPWpGaD
